A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Recruiting · Phase 1 · NCT05685173
Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
At a glance
- Research payments reported, 2025
- $494,085
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 107
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Odronextamab (drug), REGN5837 (drug)
- Dates
- Started 2023-04-20; completion 2030-01-13
- Results posted
- Not yet
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in…
From ClinicalTrials.gov, last updated 2026-05-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $494,085 in research payments for this study in 2025 (106 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John Baird, MD Hematology · Duarte, CA
- John M. Timmerman, MD Hematology & Oncology · Los Angeles, CA
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Jeremy S. Abramson, MD Medical Oncology · Boston, MA
- Joshua Brody, M.D. Medical Oncology · New York, NY
- Catherine S. Diefenbach, M.D. Hematology & Oncology · New York, NY
- Matthew J. Matasar, M.D. Medical Oncology · New York, NY
- Farrukh T. Awan, M.D., M.S. Hematology & Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $134,735
- Dana Farber Mass General Brigham Cancer Care Inc $109,977
- University of Texas Southwestern Medical Center $92,360
- Mount Sinai School of Medicine $57,143
- Rutgers the State University of New Jersey $39,305
- Norton Healthcare Inc $34,134
- Resnick Neuropsychiatric Hospital at UCLA, CA $13,879
- New York University School of Medicine $12,552
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.